Research programme: microencapsulated cell therapy - diabetes - PharmaCyte Biotech

Drug Profile

Research programme: microencapsulated cell therapy - diabetes - PharmaCyte Biotech

Alternative Names: Bio-artificial pancreas - PharmaCyte Biotech; Encapsulated cell therapy - diabetes - PharmaCyte Biotech

Latest Information Update: 13 May 2016

Price : $50

At a glance

  • Originator Nuvilex
  • Developer PharmaCyte Biotech; University of Veterinary Medicine, Vienna
  • Class Cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 12 May 2016 PharmaCyte Biotech receives patent allowance for the use of Melligen cells for the treatment of Diabetes in USA
  • 15 Jul 2015 PharmaCyte Biotech has patent protection for Melligen cells in Europe, France, Switzerland, Great Britain, Ireland, Germany, Spain, Denmark, Italy and the Netherlands
  • 23 Jun 2015 PharmaCyte enters into a research service agreement with the University of Technology Sydney to develop microencapsulated cell therapy for the treatment of type 1 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top